Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to help people with disabilities suffering from uncontrollable movements

NCT ID NCT06997198

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 34 times

Summary

This study tests a drug called deutetrabenazine for tardive dyskinesia (uncontrollable movements) in 25 adults with intellectual/developmental disabilities and psychiatric or behavioral disorders. Participants will take the medication for 24 weeks to see if it reduces movement problems and improves daily life. The goal is to find a safe and effective treatment for this group, who often have trouble with standard movement exams.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospitals of Cleveland

    Cleveland, Ohio, 44106, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

Caregiver Burden developmental disability intellectual disability movement disorder tardive dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.